Kara Caner, Şen Emine Malkoç, Elgin Kadriye Ufuk, Serdar Kurtuluş, Yilmazbaş Pelin
Department of Ophthalmology, Etlik Zubeyde Hanim Women's Health Education and Research Hospital, Yeni Etlik Caddesi No: 55, Etlik, Keçiören, 06010, Ankara, Turkey.
Ulucanlar Eye Research and Training Hospital, Ankara, Turkey.
Int Ophthalmol. 2017 Jun;37(3):619-626. doi: 10.1007/s10792-016-0315-3. Epub 2016 Aug 9.
The purpose of the study is to assess the changes in the long-term effects of prostaglandin analogues (PGAs) on intraocular pressure (IOP) reduction in patients with primary open-angle glaucoma (POAG). Data of POAG patients treated with latanoprost (0.005 %), travoprost (0.004 %), or bimatoprost (0.03 %) as the first line treatment for 5 years or more were retrospectively evaluated. Baseline ophthalmic assessment values were recorded together with the IOP at the 6th month, 1st year, and then annually. The 79 patients included 33 (41.8 %) men and 46 (58.2 %) women. There were 34 (43.0 %) patients using latanoprost (0.005 %), 23 (29.1 %) patients using bimatoprost (0.03 %), and 22 (27.8 %) patients using travoprost (0.004 %). There was no difference between the groups in terms of age, gender, or baseline IOP levels. IOP levels at the 6th month were significantly lower than baseline IOP levels in all groups (p < 0.01, Friedman test). The IOP decrease was maintained after the 6th month in all three group with no statistically significant difference compared to the 6th month IOP value (p > 0.05, Friedman test) and no statistically significant difference between the groups during follow-up (Kruskal-Wallis test, p > 0.05). IOP reductions with PGAs were adequate and stable in the 5-year follow-up period with no decrease in effectiveness over time.
本研究的目的是评估前列腺素类似物（PGA）对原发性开角型青光眼（POAG）患者降低眼压（IOP）的长期效果变化。对接受拉坦前列素（0.005%）、曲伏前列素（0.004%）或比马前列素（0.03%）作为一线治疗5年及以上的POAG患者的数据进行回顾性评估。记录基线眼科评估值以及第6个月、第1年及之后每年的眼压。79例患者中，男性33例（41.8%），女性46例（58.2%）。使用拉坦前列素（0.005%）的患者有34例（43.0%），使用比马前列素（0.03%）的患者有23例（29.1%），使用曲伏前列素（0.004%）的患者有22例（27.8%）。各组在年龄、性别或基线眼压水平方面无差异。所有组在第6个月时的眼压水平均显著低于基线眼压水平（p<0.01，Friedman检验）。所有三组在第6个月后眼压持续降低，与第6个月时的眼压值相比无统计学显著差异（p>0.05，Friedman检验），且随访期间各组之间无统计学显著差异（Kruskal-Wallis检验，p>0.05）。在5年随访期内，PGA降低眼压的效果充分且稳定，未随时间推移而降低。
